Showing 4091-4100 of 6036 results for "".
- Oculis Accelerates Enrollment for Phase 3 DIAMOND Trials of OCS-01 Eye Drops in DMEhttps://modernod.com/news/oculis-accelerates-enrollment-for-phase-3-diamond-trials-of-ocs-01-eye-drops-in-diabetic-macular-edema/2482504/Oculis announced significant progress in patient enrollment for both phase 3 DIAMOND trials of OCS-01 eye drops in diabetic macular edema (DME). The DIAMOND program, designed to assess the efficacy and safety of OCS-01, an investigational eye drop, has enrolled about 70% of patients in the phase
- Regenxbio Reports Positive Phase 2 Data on ABBV-RGX-314 for Bilateral Wet AMDhttps://modernod.com/news/regenxbio-reports-positive-phase-2-data-on-abbv-rgx-314-for-bilateral-wet-amd/2482503/Regenxbio announced results from the phase 2 fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314, a gene therapy candidate, in patients with bilateral wet age-related macular degeneration (AMD). The data was presented at the American Academy of Ophthalmology (AAO) me
- Google’s Diabetic Retinopathy AI Model Licensed for Use in India and Thailandhttps://modernod.com/news/googles-diabetic-retinopathy-ai-model-licensed-for-use-in-india-and-thailand/2482497/Google announced the licensing of its diabetic retinopathy artificial intelligence (AI) model to healthcare providers and health-tech partners. According to Google, during the next 10 years, Forus Health, AuroLab, and Perceptra will aim to deliver a combined 6 million AI-supported scree
- Glaukos Announces Positive Phase 3 Results for Epioxa Corneal Cross-Linking Therapyhttps://modernod.com/news/glaukos-announces-positive-phase-3-results-for-epioxa-corneal-cross-linking-therapy/2482495/Glaukos announced that its second phase 3 confirmatory pivotal trial for Epioxa (Epi-on), a next-generation corneal cross-linking therapy for the treatment of keratoconus, has met its primary efficacy endpoint. The trial demonstrated a statistically significant and clinically
- Ikerian and RetinAI Secure $8M Financing to Drive AI Healthcare Innovationhttps://modernod.com/news/ikerian-and-retinai-secure-8m-financing-to-drive-ai-healthcare-innovation/2482494/Switzerland-based Ikerian AG and its subsidiary RetinAI US, announced the successful first close of their Series B financing round, securing USD $8 million (CHF 6.73 million). With the newly secured funding, Ikerian said it is set to fast-track the development of its flagship produ
- Ocular Therapeutix Announces Accelerated Timelines for SOL-1 Registrational Trial of Axpaxli in Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-accelerated-timelines-for-sol-1-registrational-trial-of-axpaxli-in-wet-amd/2482490/Ocular Therapeutix announced an acceleration of the SOL-1 phase 3 registrational clinical trial of Axpaxli for wet age-related macular degeneration (wet AMD). The company now expects to complete enrollment and randomization by the end of 2024, ahead of previous guidance to finish by the first qua
- Oculis to Provide Update on DIAMOND Phase 3 Program for OCS-01 Eye Drops at Innovate Retina and Eyecelerator 2024https://modernod.com/news/oculis-to-provide-update-on-diamond-phase-3-program-for-ocs-01-eye-drops-at-innovate-retina-and-eyecelerator-2024/2482488/Oculis announced an update on its DIAMOND phase 3 program for OCS-01, a high-concentration dexamethasone eye drop formulated with OPTIREACH technology for the treatment for diabetic macular edema (DME). David Eichenbaum, MD, an expert in retina diseases, will present new insig
- Centricity Vision Unveils Enhancements to ZEPTOLink IOL Positioning System at AAO 2024https://modernod.com/news/centricity-vision-unveils-enhancements-to-zeptolink-iol-positioning-system-at-aao-2024/2482487/Centricity Vision announced platform enhancements for its ZEPTOLink IOL Positioning System designed to reduce treatment time by up to 60%. The enhancements will be highlighted at the American Academy of Ophthalmology (AAO) annual meeting, taking place from October 18-21, 2024, in Chicago.
- Heidelberg Engineering Receives FDA Clearance for Spectralis Flex Module for Supine Imaginghttps://modernod.com/news/heidelberg-engineering-receives-fda-clearance-for-spectralis-flex-module-for-supine-imaging/2482486/Heidelberg Engineering has received FDA clearance for its Spectralis Flex Module, a multimodal diagnostic imaging platform. The new module is designed specifically for imaging the posterior segment of both pediatric and adult patients in a supine position, addressing a need for patients unab
- RetinaLyze Launches Advanced Glaucoma Progression AIhttps://modernod.com/news/retinalyze-launches-advanced-glaucoma-progression-ai/2482480/RetinaLyze has introduced the Advanced Glaucoma Progression AI. Central to this technology is the 'Glaucoma Index of Progression' (GIP), a tool designed to provide a stable and consistent method for tracking glaucoma progression over time. Glaucoma, often referred to a